Houede, N., Chevallier, T., Loic, J., Thibault, C., Yann, N., Jaillon, C. A., Masson-Lecomte, A., Gravis, G., Tartas, S., Pouessel, D., Laguerre, B., Audenet, F., Xylinas, E., Guillaume, L., Roupret, M. (2025). Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.661